Crizotinib is an anaplastic lymphoma kinase (ALK) inhibitor, which has brought marked clinical benefits to patients with adult non-small cell lung cancer with *ALK* rearrangement.^[@bib1]^ The *ALK* gene is located on chromosome 2p23 and its rearrangements with variable fusion partners have been identified in various malignant diseases such as anaplastic large cell lymphoma, inflammatory myofibroblastic tumors and neuroblastoma.^[@bib2]^ The potential efficacy of crizotinib for these diseases has been reported.^[@bib2],\ [@bib3],\ [@bib4]^ Myeloid neoplasms with *ALK* rearrangement are uncommon but several reports indicate that crizotinib is effective for these diseases.^[@bib5],\ [@bib6]^ The efficacy of an ALK inhibitor on leukemia cells with *ALK* rearrangement has been shown *in vitro*.^[@bib6]^ Furthermore, crizotinib reduced leukemia cells in acute myeloid leukemia (AML) with *ALK* rearrangement.^[@bib5]^

Here we report a pediatric patient with relapsed and refractory AML with RAN-binding protein 2 (*RANBP2*)-*ALK* fusion with monosomy 7, who achieved complete remission (CR) after treatment with crizotinib and allogeneic hematopoietic cell transplantation (allo-HCT).

A previously healthy 2-year-old female developed fatigue and a respiratory disorder. Her blood tests showed marked leukocytosis and anemia, and she was referred to our department. Her laboratory results were as follows: hemoglobin level 3.5 g/dl, platelet count 10 × 10^3^/μl and leukocyte count 159 × 10^3^/μl with 39% blast cells. A bone marrow aspirate showed hypercellularity with leukemia cells. The patient was diagnosed as acute myelomonocytic leukemia. The karyotype determined by G-banding was 45,XX,inv(2)(p23q13), which indicates *ALK* rearrangement, in all 20 cells analyzed. Other gene abnormalities, including monosomy 7, were not detected.

The patient was treated in accordance with Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 protocol.^[@bib7]^ After induction therapy, hematological CR was achieved and further G-banding analysis revealed a normal karyotype. The first relapse occurred 6 months after diagnosis, during consolidation therapy. In addition to inv(2)(p23q13), monosomy 7 was identified by fluorescence *in situ* hybridization. The patient received IDA-FLAG (Idarubicin, 10 mg/m^2^, on days 1 and 2; fludarabine, 30 mg/m^2^, on days 1--5; and cytarabine, 2 g/m^2^, once daily on days 1--5. Granulocyte colony-stimulating factor, 300 mg/m^2^, was administered daily beginning 1 day before the commencement of chemotherapy and continued until a neutrophil count of \>500/μl), and azacitidine as salvage therapy; however, these proved ineffective.

Because the patient\'s leukemia cells carried *ALK* rearrangement and were refractory to conventional salvage therapy, we decided to administer crizotinib based upon its potential efficacy for the disease.^[@bib5]^ After the approval of an institutional review board and written informed consent from her guardians, the patient received crizotinib, 280 mg/m^2^, twice a day, without concomitant chemotherapy except for intrathecal therapy (12 mg methotrexate, 25 mg cytarabine and 10 mg hydrocortisone). The dose of crizotinib used was determined based on phase I clinical trials by the Children\'s Oncology Group.^[@bib4]^

Complete cytogenetic remission (disappearance of monosomy 7 in fluorescence *in situ* hybridization of bone marrow aspirate) was confirmed 51 days after the initiation of crizotinib. Severe adverse reactions did not occur except for nausea and vomiting. Subsequently the patient underwent allo-HCT from the 5/8 HLA-matched mother. Crizotinib was administrated for 55 days in total and discontinued 6 days before the initiation of a conditioning regimen, with total body irradiation of 12 Gy and 90 mg/m^2^ melphalan for 2 days. HCT was well tolerated, and neutrophil engraftment was achieved on day 29. Complete donor chimerism and the absence of monosomy 7 in a bone marrow aspirate was confirmed on day 28. CR has remained for more than 1 year after the HCT.

The presence of *RANBP2-ALK* fusion gene was confirmed by PCR with reverse transcription of a bone marrow sample at diagnosis and a relapse ([Figure 1a](#fig1){ref-type="fig"}).^[@bib8]^ The *RANBP2-ALK* fusion gene disappeared after 51 days of administration of crizotinib and remained negative after HCT ([Figure 1b](#fig1){ref-type="fig"}).

This is the first pediatric case suggesting the effectiveness of crizotinib and HCT for relapsed and refractory AML with *ALK* rearrangement.

The potential efficacy of crizotinib for hematological malignancies with *ALK* rearrangement has been reported previously. In a pediatric phase I trial, seven out of eight patients with *ALK*-positive anaplastic large cell lymphoma achieved a CR after treatment with crizotinib.^[@bib4]^ Maesako *et al.*^[@bib5]^ reported the efficacy of crizotinib in reducing leukemia cells in AML with *ALK* rearrangement. However, resistance to crizotinib due to a secondary ALK kinase domain mutation occurred.^[@bib5],\ [@bib9]^ The authors consequently suggested the necessity of consolidation therapy using cytotoxic agents to achieve long-term remission.^[@bib5]^ Allogeneic HCT is also a tolerable and curative option after crizotinib therapy, as reported in a case of refractory anaplastic large cell lymphoma.^[@bib3]^ Our case achieved CR by crizotinib administration only and then successfully underwent subsequent HCT.

A *RANBP2-ALK* fusion gene combined with monosomy 7 may be responsible for a certain type of hematologic disorder, such as acute myelomonocytic leukemia, and be related to a poor prognosis.^[@bib10],\ [@bib11]^ Clinical data for our patient and five other previously reported patients^[@bib5],\ [@bib10],\ [@bib11]^ showing a myeloid neoplasm with *ALK* rearrangement are summarized in [Table 1](#tbl1){ref-type="table"}. The neoplasms of all patients, including our case, were accompanied by monosomy 7 and were resistant to multidrug cytotoxic chemotherapy. Maxson *et al.*^[@bib6]^ identified an oncogenic *ALK* point mutation in adult AML and pediatric B-cell acute lymphoblastic leukemia, and suggested that *ALK* mutations likely require other cooperating mutations for progression to leukemia. Monosomy 7, a potentially unfavorable prognostic factor in AML and juvenile myelomonocytic leukemia, may, in our patient, have a role as the cooperating mutation, together with *ALK* rearrangement, which leads to resistance to standard cytotoxic chemotherapy.

The prognosis of AML with monosomy 7 is dismal; however, our patient successfully achieved molecular CR by crizotinib monotherapy treatment and maintained CR for more than a year after HCT. Crizotinib can be viewed as a promising treatment option for those high-risk patients with *ALK* rearrangement. Therefore, we suggest examining *ALK* rearrangement and using crizotinib in patients with a refractory or relapsed myeloid neoplasm and chromosome 2p23 aberration. Further studies of the use of crizotinib in AML with *RANBP2-ALK* fusion gene are required to enhance our understanding of the contribution of crizotinib to the successful treatment of this disease.
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![(**a**) Sanger sequencing of RANBP2-ALK fusion transcripts. The breakpoint lies between *RANBP2* exon 16 and *ALK* exon 20. (**b**) RT-PCR for *RANBP2-ALK* fusion transcripts in bone marrow aspirate samples. Total cellular RNA was extracted from leukemia blast cells with an RNeasy Mini Kit (QIAGEN, Tokyo, Japan). For RT-PCR analysis, 500 ng of total RNA was reverse-transcribed by PrimeScriptTM RT Master Mix according to the manufacturer\'s instructions (TaKaRa Bio, Tokyo, Japan). PCR reactions contained cDNA template, TaKaRa Ex Taq (TaKaRa Bio), 10 × Ex Taq buffer (TaKaRa Bio), dNTPs (TaKaRa Bio), forward primer (5′-CATTCTACACCGTCTCCTACCAG-3′) and reverse primer (5′-CGAGGTGCGGAGCTTGCTCAGC-3′) in a 50 μl reaction.^[@bib8]^ The cycling conditions were as follows: one cycle of 94 °C for 5 min; 30 cycles of 94 °C for 30 s, 60 °C for 30 s and 72 °C for 30 s; and one cycle of 72 °C for 7 min. Sequencing of the PCR product was performed by FASMAC Co., Ltd. (Kanagawa, Japan). CR, complete remission; HCT, hepatopoietic cell transplantation; RT-PCR, reverse transcription-PCR.](bcj201652f1){#fig1}

###### Characteristics of patients with myeloid malignancies and the *RANBP2-ALK* fusion gene

  *Characteristic*                 *This case*                                                                           *Maesako et al.*^[@bib5]^                                                                         *Lim et al.*^[@bib10]^                                     *Rottgers et al.*^[@bib11]^ *Patient 3*   *Patient 4*                                     *Patient 6*
  -------------------------------- ------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- ---------------------------------------------------------- ----------------------------------------- ----------------------------------------------- ------------------------------------------------------------------------------
  Diagnosis                        AML (M4)                                                                              AML                                                                                               AML (M4)                                                   MDS or JMML                               AML (M4)                                        JMML
  Karyotype                        46,XX,inv(2)(p23q13) \[20\] (at diagnosis) 45,XX,inv(2)(p23q13), -7 \[5\] (relapse)   46, XX, inv(2)(p23q13) \[1\]/, 45, idem, -7 \[8\]/,46, idem, -7, +mar \[1\]                       45,XX,inv(2)(p23q13),-7 \[20\]                             45,XY,inv(2) (p23q13),-7 \[5\]            46,XY,inv(2)(p23q13) \[3\]/, 45,idem,-7 \[8\]   45,XY,t(2;2) (p23;q11\~13),-7
  Age at diagnosis                 2.8 Years                                                                             75 Years                                                                                          31.4 Years                                                 8 Years                                   16.3 Years                                      3.5 Years
  Initial therapy regimen          VP-16, Ara-C, IDA                                                                     Ara-C, DNR, AZA (every 4 weeks)                                                                   Ara-C, DNR                                                 Ara-C, DNR, VP-16                         Ara-C, DNR, VP-16                               Ara-C, DNR, VP-16
  Response to initial therapy      Relapse 6 months after diagnosis, during consolidation therapy                        Relapse after eight cycles of AZA                                                                 Induction failure                                          Recurrence of blasts on day 26            Early relapse after 6 months                    Low persistent blast cells ranging between 2 and 6% during the next 4 months
  Salvage therapy regimen          IDA+FLAG, AZA, Crizotinib                                                             Crizotinib                                                                                        Ara-C, MIT, VP-16                                          ---                                       liposomal DNR, FLU, Ara-C                       ---
  Response to crizotinib therapy   Molecular CR after 51 days crizotinib                                                 Blasts disappeared from peripheral blood after 71 days crizotinib: blasts reappeared on day 135   ---                                                        ---                                       ---                                             ---
  HCT                              HCT from HLA5/8 matched mother                                                        ---                                                                                               MUD HCT                                                    ---                                       MFD HCT                                         MUD HCT
  Clinical outcome                 Alive 1 year after HCT                                                                No data                                                                                           Relapse 3 months after HCT; death 7 months after relapse   Early death due to infection              Alive 6 years after HCT                         Alive 8 years after HCT

Abbreviations: AML, acute myeloid leukemia; Ara-C, cytarabine; AZA, azacitidine; DNR, daunorubicin; FLAG, fluradabine, cytarabine and granulocyte colony-stimulating factor; FLU, fludarabine; HCT, hematopoietic cell transplantation; JMML, juvenile myelomonocytic leukemia; MDS, myelodysplastic syndromes; MFD, matched family donor; MIT, mitoxantrone; MUD, matched unrelated donor; VP-16, etoposide.
